latest news on tirzepatide FDA Grants a New Indication for Obesity Management Tirzepatide is a New Medication

The policy marks a shift from earlier positions that excluded anti-obesity drugs from Medicare and Medicaid coverage

Because these bulk quantities contain the equivalent of millions of individual doses, even a single enforcement failure at this scale introduces massive systemic risk to public safety

The government also retains march-in rights, which allow it to demand compulsory licensing to a third party if the patent owner fails to achieve practical application of the invention within a reasonable period

We employed a 95% confidence interval for all statistical comparisons, reporting the error as the standard error of the mean

In humans, pre-proglucagon has 180 amino acids and is cleaved to yield proglucagon (158 amino acids), which lacks the N-terminal signalling sequence

Mounjaro and Zepbound are the only FDA-approved tirzepatide products, and all dose strengths are currently available